[18F]FPyQCP: A Robust FAP-Targeted PET Tracer Integrating Covalent C−18F Labeling and Radiometal Chelation for Enhanced In Vivo Performance
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c01795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Sangeeta Ray Banerjee und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland21287, United States. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Fluorine Radioisotopes, Radiopharmaceuticals, Serine Endopeptidases. Die Arbeit nennt 74 Literaturangaben. Gefördert von: NIBIB NIH HHS, Precision Molecular, Inc., National Institute of Biomedical Imaging and Bioengineering.
Abstract (Originalsprache)
Fibroblast activation protein (FAP) is a validated PET imaging target for the tumor microenvironment. Currently, most 18F-labeled FAP PET agents use Al−F chemistry, with Al18F-FAPI-74 leading clinically, whereas C−18F tracers perform less effectively. Here, we developed (4-quinolinoyl)glycyl-2-cyanopyrrolidine (QCP)-based inhibitors incorporating a 6-fluoronicotinamide prosthetic group for stable C−18F labeling. Chelator incorporation improved hydrophilicity and enabled structurally matched radiometal- and 18F-labeled analogs from a common scaffold. The compounds exhibited high FAP inhibitory capacity (Ki = 9.9−56.7 pM) and favorable physicochemical properties (Log P7.4 = −3.1 ± 0.1). The lead tracer, [18F]FPyQCP, was prepared by a one-pot, two-step radiosynthesis in 50−80% yields, with >99% radiochemical purity and molar activity of 74−200 GBq/μmol. In U87 xenografts, [18F]FPyQCP achieved high tumor uptake (23.3 ± 2.1 %ID/g) and favorable tumor-to-blood ratios (12.0 ± 0.3) at 2 h. This modular labeling strategy establishes a versatile platform for next-generation FAP PET tracers and beyond.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland21287, United States.
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland21287, United States.
- Department of Radiology, UT Southwestern Medical Center, Dallas, Texas75390, United States.
ORCID-Profile: Sangeeta Ray Banerjee, Il Minn, Deepankar Das, Laurence Carroll, Hyojin Cha, Andrew G Horti, Martin G Pomper
Förderung
- NIBIB NIH HHS
- Precision Molecular, Inc.
- National Institute of Biomedical Imaging and Bioengineering
Zitieren
APA
Banerjee, S. R., Boinapally, S., Minn, I., Das, D., Carroll, L., Thotakura, A. K., Cha, H., Lisok, A., Singh, R., Alati, S., Nam, H., Du, Y., Horti, A. G., & Pomper, M. G. (2026). [18F]FPyQCP: A Robust FAP-Targeted PET Tracer Integrating Covalent C−18F Labeling and Radiometal Chelation for Enhanced In Vivo Performance. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01795
Vancouver
Banerjee SR, Boinapally S, Minn I, Das D, Carroll L, Thotakura AK, et al. [18F]FPyQCP: A Robust FAP-Targeted PET Tracer Integrating Covalent C−18F Labeling and Radiometal Chelation for Enhanced In Vivo Performance. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01795
BibTeX
@article{Banerjee2026,
author = {Banerjee, Sangeeta Ray and Boinapally, Srikanth and Minn, Il and Das, Deepankar and Carroll, Laurence and Thotakura, Anand K and Cha, Hyojin and Lisok, Alla and Singh, Rajan and Alati, Suresh and Nam, Hwanhee and Du, Yong and Horti, Andrew G and Pomper, Martin G},
title = {[18F]FPyQCP: A Robust FAP-Targeted PET Tracer Integrating Covalent C−18F Labeling and Radiometal Chelation for Enhanced In Vivo Performance},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01795}
}
EUVIMED